Radient Pharmaceuticals (RPC) Tops Q4 EPS by 26c

Radient Pharmaceuticals (NYSE: RPC) reported Q4 EPS of $0.26. Revenue for the quarter came in at $81 million.

For earnings history and earnings-related data on Radient Pharmaceuticals (RPC) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• Teva shares Phase 3 data on once-monthly schizophrenia injection
• Ximen Mining launches $350,000 bridge placement for Kenville mine